Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application symbols : Bgne save search
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
Published: 2024-02-27 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.93%
H: 9.05%
C: 8.94%
tevimbra fda license application
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Published: 2023-12-13 (Crawled : 21:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.91%
H: 2.03%
C: 1.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: -1.78%
fda lung review cancer cell application grants advanced
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.27%
H: 0.99%
C: -0.67%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.06%
C: -1.01%
lumakras fda treatment meeting application
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
Published: 2021-09-13 (Crawled : 07:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.0%
H: 4.26%
C: 3.47%
fda fda acceptance license application cell carcinoma
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer
Published: 2021-08-23 (Crawled : 05:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -7.09%
H: 7.52%
C: 6.77%
china cancer license application
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
Published: 2021-07-08 (Crawled : 05:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.71%
H: 4.93%
C: 3.36%
china license application cell carcinoma
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
Published: 2021-05-19 (Crawled : 12:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -2.2%
H: 1.41%
C: 1.21%
new drug fda fda acceptance brukinsa drug application
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
Published: 2021-05-10 (Crawled : 16:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.63%
H: 0.95%
C: -2.15%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.38%
H: 0.27%
C: -0.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.7%
H: 1.1%
C: -1.32%
fda license application
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
Published: 2021-02-17 (Crawled : 14:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: -6.37%
fda drug fda acceptance new drug brukinsa application
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.